This site is intended for health professionals only
Tuesday 18 December 2018
Share |

Latest News

European Commission approval for self-administration of Xolair® across all indications

Monday 17th December 2018
Novartis has announced that the European Commission (EC) has approved Xolair® (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) to administer their own treatment.
With this approval, Xolair is the first and only biologic to offer the option of self-administration for SAA and CSU.
Thu, 22 Nov 2018
PICO is suitable for use in both hospital and community settings, and is approved for a number of indications, including surgically closed incision sites
Thu, 22 Nov 2018
This is the first sNPWT system to include an innovative integrated Y extension enabling the utilisation of two dressings concurrently from one pump, in practice allowing for two wounds to be addressed at the same time, thereby potentially reducing cost
Tue, 20 Nov 2018
1 in 100 people in the UK has coeliac disease but half a million people in the UK are undiagnosed
Tue, 20 Nov 2018
PALISADE (Peanut Allergy oral Immunotherapy Study of AR101 for Desensitization) was an international, randomised (3:1), double-blind, placebo-controlled, Phase III trial to evaluate the efficacy and safety of AR101 in patients with peanut allergy
Tue, 20 Nov 2018
Galcanezumab is a humanised monoclonal antibody that binds to the calcitonin gene-related peptide, which plays a role in migraine attacks, blocking its downstream function
Mon, 19 Nov 2018
NHS trusts face staff shortage of more than 350,000 by 2030, think tanks warn